Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 28, 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific executive transaction rather than a financial performance report.
Material Changes
The material change disclosed is a reduction in the shareholding of an Executive Director:
- Executive: Sir Andrew Witty
- Transaction: Sale of 10,000 Ordinary Shares
- Date: April 28, 2016
- Price: £14.75 per Ordinary Share
Guidance, Outlook, and Management Commentary
There is no guidance, outlook, or general management commentary regarding the company's future performance in this filing. The only commentary provided relates to the executive's compliance with share ownership requirements:
- Following the sale, Sir Andrew Witty's resulting shareholding remains more than ten times his base salary.
- This holding is well in excess of the required ownership threshold of four times his base salary.
Investor Verification Checklist
- Verify the total number of shares held by Sir Andrew Witty post-transaction to confirm the "more than ten times base salary" claim.
- Confirm the prevailing market price of GSK Ordinary Shares on April 28, 2016, to validate the £14.75 transaction price.
- Review the company's specific share ownership policy for Executive Directors to ensure the "four times base salary" requirement is accurate.